title: Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
abstract: Little is known about outcomes of patients with chronic lymphocytic leukemia (CLL) with del(17p13.1) karyotype at diagnosis. We reviewed 114 de novo del(17p13.1) CLL patients seen at our institution. Using proportional hazards models to identify pretreatment clinical variables significantly associated with treatment-free survival (TFS) and overall survival (OS), we developed a simplified risk score for de novo del(17p13.1) CLL patients to predict TFS and OS based on these variables. These scores, particularly the very highest, can be utilized to identify high-risk patients for expedient enrollment on clinical trials. Our data support careful observation for low-risk patients, potentially preventing unnecessary use of aggressive therapies.
authors.affiliation: Division of Hematology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
authors.forename: Deborah M
authors.initials: DM
authors.lastname: Stephens
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.
authors.forename: Amy S
authors.initials: AS
authors.lastname: Ruppert
authors.affiliation: Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: William G
authors.initials: WG
authors.lastname: Weirda
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Jones
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Woyach
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
authors.forename: Kami
authors.initials: K
authors.lastname: Maddocks
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
authors.forename: Samantha M
authors.initials: SM
authors.lastname: Jaglowski
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Andritsos
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Flynn
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Grever
authors.affiliation: Division of Hematopathology, Department of Pathology, Ohio State University, Columbus, Ohio.
authors.forename: Gerard
authors.initials: G
authors.lastname: Lozanski
authors.affiliation: Division of Medicine, Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: Constantine
authors.initials: C
authors.lastname: Tam
authors.affiliation: Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.affiliation: Division of Cancer Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Keating
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
authors.forename: Natarajan
authors.initials: N
authors.lastname: Muthusamy
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.
authors.forename: Lynne V
authors.initials: LV
authors.lastname: Abruzzo
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Cytogenetics, Department of Pathology, Ohio State University, Columbus, Ohio.
authors.forename: Nyla A
authors.initials: NA
authors.lastname: Heerema
authors.affiliation: Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.|Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio.|Division of Medicinal Chemistry, College of Pharmacy, Ohio State University, Columbus, Ohio.
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D002886:Chromosomes, Human, Pair 17; D005260:Female; D006801:Humans; D059785:Karyotype; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012306:Risk; D017384:Sequence Deletion; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents